AGRX:NSD-Agile Thrpe (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 0.67

Change

+0.03 (+4.79)%

Market Cap

USD 2.91M

Volume

0.02B

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

AGRX Stock Forecast & Price:
Based on the Agile Thrpe stock forecasts from 1 analysts, the average analyst target price for Agile Thrpe is USD 0.00 over the next 12 months. Agile Thrpe’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Agile Thrpe is Very Bearish, which is based on 0 positive signals and 5 negative signals. At the last closing, Agile Thrpe’s stock price was USD 0.67. Agile Thrpe’s stock price has changed by -72.15% over the past week, -47.57% over the past month and -98.76% over the last year.

About Agile Thrpe (AGRX:NSD)

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive p ...Read More

Company Website : https://www.agiletherapeutics.com

Address : 101 Poor Farm Road, Princeton, NJ, United States, 08540

Employees : 30

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.60

52 Week High : 55.60

Short Ratio : 1.77

52 Week Low : 0.61

Shorted Shares : 481,594

200 Day Moving Average : 16.12

Shorted Shares Previous Month : 502,607

50 Day Moving Average : 1.83

Shares Held By Insiders : 1.04%

Short Percentage : 10.60%

Shares Held by Institutions : 34.72%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-07-05 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NBIX Neurocrine Biosciences Inc

-0.95 (-0.96%)

 USD9.49B 134.12 70.22
MYL Mylan N.V

N/A

 USD8.59B 30.73 11.86
APHA Tilray, Inc

N/A

 USD6.86B 60.60 454.68
MNTA Momenta Pharmaceuticals, Inc

N/A

 USD6.24B N/A N/A
ITCI Intracellular Th

+1.92 (+3.48%)

 USD5.20B N/A -14.65
PCRX Pacira Pharmaceuticals Inc

+0.50 (+0.86%)

 USD2.63B 69.70 24.90
HCM HUTCHMED DRC

+1.14 (+8.48%)

 USD2.33B 17.69 -6.47
ALVO Alvotech Ordinary Shares

-0.81 (-8.48%)

 USD2.01B N/A -139.58
IRWD Ironwood Pharmaceuticals Inc

+0.34 (+2.95%)

 USD1.77B 3.64 7.08
AMPH Amphastar P

-0.69 (-1.95%)

 USD1.73B 21.04 12.10

ETFs Containing AGRX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -96.56% 1% F N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -96.56% 1% F N/A N/A
Trailing 12 Months  
Capital Gain -98.68% 1% F N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -98.68% 1% F N/A N/A
Trailing 5 Years  
Capital Gain -99.55% 7% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.55% 7% F 1% F
Average Annual (5 Year Horizon)  
Capital Gain 23.20% 82% B- 79% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.20% 82% B- 79% C+
Risk Return Profile  
Volatility (Standard Deviation) 126.86% 16% F 10% F
Risk Adjusted Return 18.29% 69% D+ 51% F
Market Capitalization 2.91M 1% F 1% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.57 58% F 51% F
Price / Cash Flow Ratio -0.04 26% F 50% F
EV/EBITDA -0.19 37% F 59% F
Management Effectiveness  
Return on Equity -367.94% 6% F 3% F
Return on Invested Capital -154.67% 12% F 7% F
Return on Assets -99.06% 1% F 1% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 1.77 70% C- 67% D+
Short Percent 10.60% 25% F 17% F
Beta 1.60 22% F 22% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector